The Cuban population, like others in North America and Western Europe, is aging. Incidences and prevalences of degenerative diseases such as cardio-vascular diseases, diabetes and stroke are increasing. However, Cuba faces a somewhat unique medical challenge compared with these regions. On the one hand, we have a highly-developed medical education system with about 6.7 physicians/1000 population, a rate more than twice as high as the United States (2.4/1000) and the United Kingdom (2.7/1000). 1 For example, Cuba provides more medical personnel to the developing world than all the G8 countries combined including about 19 000 physicians. 2 We also have highly-developed biomedical research institutions with world-class scientific centers such as the Finlay Institute for Vaccines Research and Production, the Center for Molecular Immunology (CIM) and the Center for Genetic Engineering and Biotechnology (CIGB) and the Latin America School of Medicine (ELAM). However, we lack economic resources for advanced medical interventions. Although our health-care expenditure as percent gross domestic product (GDP, 8.8%) is comparable to most Western European countries, it is far less than the United States (17.1%). More importantly, our per capita GDP ($18 796 USD) is much lower than the United States ($53 042 USD) and Western European countries (about $50 000 USD). 3 Consequently, per capita expenditure on health care in Cuba is only about one-third of Western European countries and of the United States. Because of this limitation we have had to develop innovative approaches to deliver newly-evolving health-care interventions such as regenerative medicine.
Our focus that in regenerative medicine is on using adult stem and progenitor cells rather than some more complex techniques such as induced pluripotent stem cells. Bone marrow from adults contains diverse cells including hematopoietic stem cells, mesenchymal stem cells, endothelial progenitor cells, side-population cells, multi-potent adult progenitor cells and very small embryonic-like stem cells. 4 Consequently, we developed a simple method for obtaining bone marrow-derived mononuclear cells as a source of stem cells for cell therapy.
Since 24 February 2004 we treated 7512 persons with diverse degenerative disorders using autologous bone marrow-derived cells. In all, 3535 (47%) infusions were for orthopedic or traumatic disorders, 3357 (45%) for vascular disorders and 620 (8%) for other disorders. In all, 610 subjects were treated in 2010, 1616 in 2011, 1014 in 2012, 528 in 2013 and 2266 in 2014 representing 545, 1443, 905, 471 and 1888 stem cell procedures per 10 million inhabitants. 5 In persons with critical arterial insufficiency of the lower limbs, major amputation was avoided in 75% of cases. In persons with chronic arterial insufficiency and intermittent claudication there was major improvement in about 85% of cases. In persons with lower limb lymph-edema many improved. 6, 7 We also observed favorable results in persons with bone cysts, complex and non-union fractures and aseptic necrosis of the hip. 6 Eighty percent of 123 subjects with knee osteoarthritis improved. 8 In five persons with stroke, autologous bone marrow mononuclear cells were injected near the lesion with some improvement including cognitive increases. 9, 10 Promising results were also seen in persons with ischemic heart disease, 6 periodontitis 6, 11 and paraplegia from spinal cord injury. We acknowledge that most of our clinical trials had no controls such that scientifically-convincing evidence of efficacy is therefore lacking. However, clinical outcomes were impressive. The method we used to obtain autologous bone marrow mononuclear cells for regenerative medicine may be useful in developing countries with limited resources. We encourage performing controlled, randomized double-blind studies to ascertain efficacy. This is our current direction.
